Paion - Commercialisation of remimazolam underway
Paion has gained approvals in the US, China and Japan for its fast-onset, short-recovery anaesthesia product remimazolam. In the US, partner Acacia...
285 Views
Paion - Remimazolam: Three major approvals
Remimazolam is approved in the US and China for procedural sedation (PS) and was launched in late July in Japan by partner Mundipharma for general...
88 Views
Paion - ByFavo – poised for autumn US launch
In a breakthrough achievement for Paion, the FDA has approved ByFavo (remimazolam) for US sale for procedural sedation (PS) taking under 30 minutes...
95 Views
Paion - Compassionate COVID-19 ICU use in Italy
As we await the FDA verdict on ByFavo (remimazolam) for procedural sedation (PS) due 5 July 2020, Paion announced in June that it will provide...
96 Views
Paion - Positive prospects with strategic uncertainties
By 5 July 2020, the FDA is due to announce its decision on remimazolam (ByFavo) for procedural sedation (PS). In Japan, Remimazolam (Anerem) was...
161 Views
No more insights